Q-omics provides the consensus-scored PODNL1 profile across patient tissues and cancer cell-line models. PODNL1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PODNL1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, PODNL1 RNA expression shows 17,454 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, COAD, and LSCC as cancer lineages where PODNL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PODNL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PODNL1 survival associations across molecular data types. PODNL1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PODNL1 RNA expression–survival associations across cancer types. High PODNL1 expression shows unfavorable associations in KIRP, KIRC, MESO, ACC, BLCA and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PODNL1 RNA expression.
This table summarizes PODNL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PODNL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PODNL1 shows higher tumor expression in COAD, HNSC, KIRC, BLCA, STAD and LUAD. The COAD box plot shows higher PODNL1 RNA expression in tumor versus normal tissue (log2 FC = +1.746, t-test p < 0.001).
This table shows molecular features associated with PODNL1 in patient tissues and cancer cell lines. In patient samples, PODNL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PODNL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
